3 ms·
Lets look at both sides of the coin here - this is research, it isn't meant to be quick. Throwing lots of money into research is about letting lots of people tr
by roenxi 4y ago
Lets look at both sides of the coin here - this is research, it isn't meant to be quick. Throwing lots of money into research is about letting lots of people try to tackle a problem to find the 1 person in the ignorant, seething mass of average humans who happens to know how. It is expected that most money on research will be wasted funding people who, in hindsight, had no idea and were doing something that was in fore- and hind- sight obviously not going to work [0].
Although, that said, I do want to stand up for the anti-government argument here. The NIH isn't going to be as effective as a private market at identifying who is effective. Everyone is affected by COVID, it isn't like they need to force people with money to take an interest in what is happening here. Ironically, although the NIH is effectively throwing people at a problem here to play the odds, we'd probably find that a private organisation is much better at it by similar logic. I'd keep an eye on the Bill & Melinda Gates Foundation myself, Gates seemed to be quite busy through COVID. Similar efforts by other wealthy people are also likely to be happening.
[0] Vulcanization is a fun example. Both in fore- and hind- sight the experiment didn't work. Dude just happened to be clumsy.
- anigbrowl 4y agoThe objection isn't that they're trying things that won't work, it's that they're not trying things. An example would be pointing out that other studies which obtained funding almost 2 years years later than the NIH have already recruited a panel of patients. I'm all for being deliberate and getting things right, but if your procedures are so elaborate that you're not getting anything done, maybe they're flawed.
- darkwizard42 4y agoThis is what I would call "the Google special" - infinite process, barely incremental progress, languishing public results
- whakim 4y agoWhy is the NIH going to be less effective than the private market at allocating research funding? Funding scientific research is a great example of a problem markets don't solve well for the exact reasons you describe. Most research doesn't lead to tangible progress (or financial reward) not because the researchers are all idiots, but because you have to try a bunch of things and a lot of them won't work, especially with poorly understood novel phenomena. Markets will instead allocate funding to the least-adventurous surest bets. That argument aside, when you allow wealthy people to dictate the direction of scientific research, you're essentially subsidizing their individual research preferences using public money (the wealthy get to take a tax deduction for contributions to their foundations).
- darkwizard42 4y agoBecause the payoff isn't in the result, it is in the initial grant...you get paid first, why does the result matter. Private capital works hard on this to gain a return. They spend first, then are under pressure to make a return. In government funded research, it often is the opposite. You get paid first...then have to deliver something (even barely trying and ending in failure) and you can then get paid again the next time grant money is available. Most research doesn't result in incremental progress as you pointed out, yet pharma companies still spend a TON of research. They live and breathe by getting to the next "big" drug to make them money and make up for all the failures. Basically, while the Gates foundation isn't the example I was thinking of, the dangling of a big payoff from the government did spur a LOT of research for COVID (see vaccine and treatment methods for COVID). Private enterprises took some breakthrough concepts (mRNA vaccines) and did a ton of ground work to test and make them viable for humans. I do strongly agree with your last point, public funded research should be directed at areas with no scalable return since private venture won't go into those areas (but having wealthy non-profits like the Gates foundation working on this is nice!)
- whakim 4y ago> Private capital works hard on this to gain a return. They spend first, then are under pressure to make a return. The key point here is "return" - in the private markets, it's just a numbers game. Most successful, important scientific research is not going to make a big return. Perhaps it'll lead to money for someone else down the line, but that's besides the point. Private markets are a bad fit for huge swathes of research where success != $$$. Which leaves a couple of areas, e.g. drug development... > pharma companies still spend a TON of research. They live and breathe by getting to the next "big" drug to make them money and make up for all the failures. While correct, it's important to remember that pharmaceutical company research spending is highly weighted towards drugs with a large number of patients or where demand is relatively insensitive to price. COVID vaccines are a perfect example because they fit both categories. This usually works out OK, but it isn't a good fit for a poorly-understood condition like long COVID where the size of the target market and the price sensitivity of the customers is very difficult to estimate. You also end up with other undesirable outcomes like the systematic underfunding of research into conditions that predominantly affect minoritized or less well-off communities. Pharmaceutical companies also rely on a huge body of publicly-funded basic research.